Global Medical Device Podcast powered by Greenlight Guru

#450: Human Factors vs. Clinical Trials: Why Your MedTech Submission is Stalling

In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story. The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data. Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments. KEY TIMESTAMPS 1. 04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management. 2. 06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status. 3. 10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release. 4. 13:15 – System errors vs. Use errors: How to identify root causes during summative studies. 5. 18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation. 6. 22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions. 7. 25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites. QUOTES "The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller "People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci Miller TAKEAWAYS 1. Premeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements. 2. Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile. 3. Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur. 4. HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams. REFERENCES 1. ISO 14971: The global standard for the application of risk management to medical devices. 2. FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation. 3. Etienne Nichols: LinkedIn Profile [https://www.linkedin.com/in/etiennenichols/] MEDTECH 101: URRA VS. UFMEA Think of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts. A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment. SPONSORS Greenlight Guru [https://www.greenlight.guru/]: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk. FEEDBACK CALL-TO-ACTION We want to hear from you! Do you have questions about your specific regulatory pathway or a topic you’d like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to podcast@greenlight.guru [podcast@greenlight.guru].

#449: 7 Pitfalls of International MedTech Expansion

In this episode, Etienne Nichols sits down with regulatory expert Mike Drues, President of Vascular Sciences, to discuss the "culture shock" international medical device companies face when entering the U.S. market. They challenge the traditional assumption that a device should always launch outside the U.S. first, noting that shifting regulatory landscapes—especially in Europe—have made the U.S. a more attractive primary entry point for many. The conversation pivots to the technical and strategic nuances of "same device, different claims." Mike explains that if a device maintains the same design but utilizes different labeling or indications for use across borders, it is technically a different device in the eyes of regulators. This creates significant complexity for Quality Management Systems and post-market surveillance, particularly concerning reporting requirements for Class III (PMA) devices. Finally, the duo explores the "trap of equivalency," where companies mistakenly assume that a CE Mark or other international approval guarantees a smooth path through the FDA. From differing consensus standards to the strategic use of OUS (Outside US) clinical data, the episode provides a roadmap for global players to synchronize their regulatory and reimbursement strategies early in the development lifecycle. KEY TIMESTAMPS 1. 01:45 - Challenging the assumption: Should you always launch outside the US first? 2. 04:12 - Defining the "International Company": Why every developer should think globally from day one. 3. 05:30 - The Labeling Trap: Why the same hardware with different claims is a different device. 4. 07:50 - Post-market surveillance nuances: Reporting OUS issues in a US PMA submission. 5. 11:15 - The "Sniff Test": Does a CE Mark actually help you with the FDA? 6. 12:40 - Leveraging Real-World Evidence (RWE) from international markets for US submissions. 7. 14:30 - The "Species Expansion" concept: Applying regulatory logic across different use cases. 8. 16:15 - Consensus Standards: Why the FDA might not recognize the "most current" version of a standard. 9. 20:00 - International Regulatory Strategy: Calculating the "lowest common denominator" for multi-country launches. 10. 25:20 - Using 100% OUS clinical data for FDA submissions: The three essential caveats. QUOTES > "If you’re marketing the same device—same design, same materials—but the labeling and claims are different in the EU versus the US, then technically, it is not the same device." - Mike Drues > "The regulatory logic is agnostic of the scenario. Whether it's a label expansion or a 'species expansion' from a dog to a human, the underlying logic remains the same." - Mike Drues TAKEAWAYS 1. Sync Your Standards: Do not assume the FDA recognizes the same version of a standard (e.g., ISO 10993-1) as international bodies. Always verify via the CDRH Recognized Consensus Standards database. 2. Design for the "Lowest Common Denominator": Identify your top 3–5 target markets early and pool their requirements to avoid redundant benchtop or clinical testing. 3. Rethink Clinical Trials: While the FDA prefers domestic data, OUS data can be used if you can prove the patient population and user profiles (physicians/nurses) are representative of the US demographic. 4. Anticipate "Off-Label" Pressure: If you market a device in Canada with claims not yet approved in the US, be prepared for US clinicians to find that information online and ask for "anticipated off-label use." REFERENCES 1. FDA Recognized Consensus Standards Database [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm]: Essential tool for verifying which versions of international standards the FDA currently accepts. 2. Greenlight Guru QMS & EDC [https://www.greenlight.guru/]: Solutions for managing complex, multi-region quality systems and clinical data. 3. Etienne Nichols’ LinkedIn [https://www.linkedin.com/in/etiennenichols/]: Connect with the host for more MedTech insights. MEDTECH 101: LABEL EXPANSION Think of Label Expansion like a smartphone software update. The hardware (the phone) stays the same, but the update allows the phone to do something it couldn't do before—like a new photography mode. In MedTech, if you have a stent approved for use in the leg (the "old label") and you want to use that same stent in the heart, you apply for a "label expansion." You aren't changing the device; you're just proving it’s safe and effective for a new job. SPONSORS: GREENLIGHT GURU This episode is brought to you by Greenlight Guru [https://www.greenlight.guru/]. Navigating international waters requires a robust foundation. Greenlight Guru’s Quality Management Software (QMS) helps you maintain a "single source of truth" for your design history files and labeling, while their Electronic Data Capture (EDC) solution streamlines the collection of the clinical data you'll need to satisfy both the FDA and international regulators. Whether you are managing post-market surveillance for a PMA or running a multi-center global trial, Greenlight Guru has you covered. FEEDBACK CALL-TO-ACTION We want to hear from you! Did this episode change your mind about your international launch strategy? Do you have a "culture shock" story from bringing a device to the US? Send your thoughts, reviews, or topic suggestions to podcast@greenlight.guru [podcast@greenlight.guru]. We read every email and love providing personalized responses to our listeners.

#448: MedTech Investment: Outcomes, Regulations, and the Shift to At-Home Care

This episode features Ivanny Franklin, Managing Partner at MedSight Capital, who brings a wealth of experience from her background in molecular biology and her decade-long tenure at NAMSA. The conversation centers on the shifting paradigms of medical device investment, specifically how the industry is moving away from service-based models toward a focus on clinical outcomes. Etienne and Ivanny explore the critical intersection of global regulatory bodies—such as the NMPA in China and the FDA in the US—and the necessity of a cohesive clinical evidence strategy. Ivanny emphasizes that for startups, understanding market-specific data requirements is not just a regulatory hurdle but a fundamental component of commercialization and investor conviction. The discussion also dives into the "patient empowerment" movement, fueled by the convergence of wearables, AI, and at-home monitoring. Ivanny shares her bullish outlook on technologies that give patients control over their data, while acknowledging the tension this creates for physicians and the ongoing need for rigorous regulatory oversight to ensure safety and effectiveness. KEY TIMESTAMPS 1. [03:15] Global Regulatory Strategy: Insights into the NMPA (formerly CFDA) and why China requires in-country clinical evidence. 2. [07:42] Leveraging Data: How to run a single clinical trial to satisfy multiple global regulatory bodies. 3. [10:18] The At-Home Monitoring Shift: The rise of wearables and OTC testing in the wake of COVID-19. 4. [13:45] The "Data Gap": Addressing the friction between patient-gathered data and physician adoption. 5. [18:22] Investment Non-Negotiables: Why revenue-generating companies and clear regulatory classifications are key for MedSight Capital. 6. [23:10] Diligence and Deception: The importance of honesty regarding reimbursement codes and 510(k) vs. PMA paths. 7. [27:45] SPV vs. Hedge Fund Models: A breakdown of how Special Purpose Vehicles allow family offices to be nimble in MedTech. QUOTES > "FDA and NMPA, for example, are quite strict in clinical evidence coming from in-country... as a startup, you really need to understand can we run a single trial with multiple global sites to achieve clearance cohesively." - Ivanny Franklin > "I’m an advocate for [at-home monitoring]. I do think that’s the future. However, there is concern around what types of information should patients be receiving and how are they going to act on that information?" - Ivanny Franklin TAKEAWAYS 1. Regulatory is the Roadmap: An investment is often "de-risked" based on the clarity of the regulatory path. If a founder cannot distinguish between a 510(k) and a PMA, it is a major red flag for investors. 2. Harmonize Your Trials: To achieve "economies of scale" in clinical evidence, work with consultants to design trials that meet the stringent requirements of both the FDA and international bodies like the NMPA early on. 3. Commercial Scalability over Hype: For revenue-generating companies, investors are less concerned with the "idea" and more focused on physician retention, training, and the cost of scaling the sales team. 4. Honesty in Reimbursement: Never "make up" or guess CPT codes. Investors utilize experts (like ex-FDA personnel) to pressure-test your reimbursement strategy during diligence. REFERENCES 1. NMPA (National Medical Products Administration): The primary regulatory body for China (formerly the CFDA). 2. NAMSA: A world-leading Medical Device CRO mentioned as Ivanny’s former professional home. 3. LSI (Life Science Intelligence): The upcoming conference mentioned where Etienne and Ivanny will speak on a panel. 4. Greenlight Guru: The preferred platform for QMS & EDC solutions [https://www.greenlight.guru] to manage medical device quality and clinical data. 5. Etienne Nichols: Connect on LinkedIn [https://www.linkedin.com/in/etiennenichols/]. MEDTECH 101: SPV (SPECIAL PURPOSE VEHICLE) Think of a Special Purpose Vehicle (SPV) like a "carpool" for investors. Instead of a massive bus (a Hedge Fund) that picks up everyone's money and decides where to go over several years, an SPV is a single car created for one specific trip—in this case, one specific company. Investors put their money into the SPV, and the SPV makes one investment in one startup. This allows smaller investors or family offices to pool their resources together to act as one large "passenger" on a company's cap table. SPONSORS This episode is brought to you by Greenlight Guru [https://www.greenlight.guru/]. Moving from a "service-based" model to an "outcome-based" model requires impeccable data and quality management. Greenlight Guru offers both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions designed specifically for the medical device industry. Whether you are gathering clinical evidence for an NMPA submission or scaling a revenue-generating product, Greenlight Guru helps you stay compliant and efficient. FEEDBACK CALL-TO-ACTION We want to hear from you! Did this breakdown of investment vehicles help you? Do you have suggestions for future MedTech topics? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, and questions to podcast@greenlight.guru [podcast@greenlight.guru].

#447: Solving the Pediatric MedTech Gap with Edwin Lindsay

In this episode, Etienne Nichols sits down with Edwin Lindsay, a seasoned MedTech operator and QARA leader, to discuss the systemic challenges facing the pediatric medical device market. Following a personal experience in a neonatal ward, Edwin highlights the stark reality that many pediatric treatments rely on adult devices adapted off-label, often leading to safety risks and clinical inefficiencies. The conversation delves into the "mismatch" of the pediatric market: these devices require the same rigorous regulatory and quality standards as adult products but offer significantly lower financial upside due to smaller patient populations. This creates a barrier for investors and manufacturers, leaving clinicians and nurses to "work miracles" with tools that aren't always fit for purpose. Despite these hurdles, Edwin shares an optimistic vision for the future. He discusses his initiative to build a collaborative network of experts—including regulatory consultants, testing houses, and grant writers—willing to provide pro-bono or at-cost support for pediatric startups. The goal is to create a streamlined regulatory roadmap that prioritizes patient safety without the prohibitive costs that currently stall innovation. KEY TIMESTAMPS 1. 00:45 – The "Pediatric Gap": Why pediatric devices have adult-level requirements but lower ROI. 2. 03:12 – Personal Insight: Edwin’s experience in the hospital and the "Guinness philosophy" of giving back. 3. 05:30 – The danger of adhesives and adapting adult materials for newborn skin. 4. 08:15 – Building a pediatric volunteer network: Testing houses and consultancies stepping up. 5. 11:40 – Regulatory Roadmaps: Navigating the age variability from premature infants to adolescents. 6. 14:50 – Off-label usage risks and the "mindset shift" required for manufacturers. 7. 18:25 – Micro-timestamp: The FDA’s Humanitarian Device Exemption (HDE) and P-Sub programs. 8. 21:10 – Real-world clinical friction: Alarm fatigue and sensor sensitivity in NICU settings. 9. 25:40 – The hidden costs: Manufacturing complexity, multiple SKUs, and low-volume production. QUOTES > "We need to give clinicians the correct tools to work their miracles. They don't want to use products off-label; they want devices actually designed for the children they are saving." - Edwin Lindsay > "If you have a pediatric project, there is a community behind you. We are breaking down the barriers of risk and cost because these babies deserve a chance." - Edwin Lindsay TAKEAWAYS 1. Regulatory Flexibility: Utilize specific FDA pathways like the Humanitarian Device Exemption (HDE) and the Pediatric Submissions (P-Sub) program to gain early feedback and specialized guidance. 2. Collaborative Cost-Sharing: Seek out "altruistic" partners; many testing houses and manufacturers are willing to work at-cost or under different financial models for pediatric-specific innovations. 3. Design for Sensitivity: Pediatric innovation isn't just about miniaturizing adult tech—it requires solving unique issues like alarm fatigue and skin sensitivity (e.g., non-damaging adhesives). 4. Workflow Integration: Engage the "head nurse" early in R&D to ensure the device fits into the high-stress environment of a pediatric ward without adding to clinical fatigue. REFERENCES 1. FDA HDE Program: A regulatory pathway for devices intended for diseases or conditions that affect small populations. 2. Greenlight Guru: The industry-leading platform for QMS & EDC solutions, helping MedTech companies maintain compliance while accelerating pediatric product development. 3. Etienne Nichols on LinkedIn: Connect with Etienne [https://www.linkedin.com/in/etiennenichols/] for more MedTech insights. MEDTECH 101: OFF-LABEL USE In the medical device world, "Off-Label" means using a device for a purpose, or on a patient population (like infants), that the FDA has not officially cleared. Think of it like this: Imagine you have a high-tech hiking boot designed for a grown man, but you have to put it on a toddler because no one makes toddler-sized hiking boots. You might be able to make it stay on with extra socks and tape, but it won't support the child’s foot correctly and might cause them to trip. In pediatrics, doctors often have to "tape the boot" because specialized devices simply don't exist. FEEDBACK CALL-TO-ACTION We want to hear from you! Are you working on a pediatric breakthrough, or have you faced challenges in this niche market? Whether you have a topic suggestion or a question for Edwin, send us an email at podcast@greenlight.guru [podcast@greenlight.guru]. We read every message and pride ourselves on providing personalized responses to our community. SPONSORS This episode is brought to you by Greenlight Guru [https://www.greenlight.guru/]. Navigating the complex regulatory landscape of pediatric devices requires a robust foundation. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions are specifically designed to help MedTech innovators manage risk and clinical data with precision. Whether you are a one-person startup or a global entity, Greenlight Guru helps you get safe, effective technology to patients faster.

#446: The Hidden Physics of the MedTech Life Cycle with Dr. Kristy Katzenmeyer-Pleuss

In this episode, Etienne Nichols sits down with Dr. Kristy Katzenmeyer-Pleuss, President and Founder of KP Medical Device Consulting, to unpack the complexities of the medical device life cycle. The conversation centers on how manufacturers often overlook critical phases of a product’s journey, such as transportation, shelf life, and the decommissioning phase, focusing instead solely on the point of patient use. Dr. Katzenmeyer-Pleuss highlights the significance of the upcoming ISO 10993-1:2025 standard and its renewed emphasis on life cycle-based risk assessments. She explains how the transition between global markets—particularly between the EU and the US—can lead to unexpected FDA deficiencies when manufacturers rely on justifications that worked for notified bodies but do not meet more stringent FDA testing expectations for reusable or in situ curing devices. The discussion concludes with actionable advice on early design decisions, such as narrowing down material suppliers and reprocessing options to reduce testing burdens. They also explore the critical need for cross-functional communication and quality system integration to ensure that learnings from one project or regulatory interaction are captured and applied across a company’s entire portfolio. KEY TIMESTAMPS 1. 01:45 – Introduction of Dr. Kristy Katzenmeyer-Pleuss and the mission of KP Medical Device Consulting. 2. 04:12 – Defining the Medical Device Life Cycle: Concept to decommissioning and the "hidden" phases in between. 3. 05:30 – ISO 10993-1:2025: The impact of the new biological evaluation standard on risk-based approaches. 4. 09:15 – Global Regulatory Discrepancies: Why a device approved in Europe might face hurdles at the FDA regarding "worst-case" testing. 5. 13:40 – Reusable Devices & Reprocessing: Managing the "permutation explosion" of cleaning agents and sterilization cycles. 6. 17:22 – Early Design Decisions: How limiting options in the IFU can significantly decrease your regulatory testing burden. 7. 21:05 – In Situ Curing Devices: The unique testing challenges of materials that change states during use. 8. 25:10 – Quality System Integration: Strategies for linking regulatory deficiencies and materials across multiple projects. QUOTES > "The life cycle is really the concept of the medical device from when it’s a concept all the way through to the end where you are disposing or decommissioning... shelf life and transport are steps that usually don’t get a lot of focus, but they are very important." - Dr. Katzenmeyer-Pleuss > "You might have one device where literally they don’t ask these questions at all, and then other times they’re very, very picky... the longer you go in that process, the harder it is to pivot without spending a lot of time and money." - Dr. Katzenmeyer-Pleuss TAKEAWAYS 1. Front-load Risk Assessments: Don’t wait for FDA deficiencies to consider how shelf life or reprocessing affects device safety; integrate these into the biological evaluation plan from day one. 2. The "Worst-Case" Strategy: When designing testing protocols for reusable devices, aim for a "worst-case" scenario that covers future iterations or additional suppliers to avoid redundant, expensive re-testing. 3. Standardize Your IFU Early: Providing users with infinite cleaning or sterilization options creates an exponential increase in testing requirements; narrow these down to the essentials to streamline market entry. 4. Break the Silos: Use your QMS to link specific material risks or regulatory feedback across different project teams so that knowledge isn't lost when personnel leave. REFERENCES 1. ISO 10993-1:2025: The updated international standard for the biological evaluation of medical devices within a risk management process. 2. Etienne Nichols on LinkedIn: Connect with the host for more MedTech insights [https://www.linkedin.com/in/etiennenichols/]. MEDTECH 101: IN SITU CURING In this episode, Dr. Katzenmeyer-Pleuss mentions In Situ Curing. Think of this like a medical-grade "liquid bandage" or dental filling. The device starts as a liquid or gel and is applied to the body, where it then hardens into a solid "in the spot" (in situ). From a regulatory standpoint, this is complex because you aren't just testing one device; you have to test the safety of the liquid, the safety of the solid, and any chemicals released during the hardening process. It is essentially three devices in one when it comes to testing. SPONSORS This episode is brought to you by Greenlight Guru [https://www.greenlight.guru/]. When navigating the complex life cycle of a medical device—from the initial risk assessments discussed today to post-market surveillance—you need a unified system. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions work together to ensure your data is linked, your testing is documented, and your clinical trials are seamless. By connecting your quality and clinical data, you can avoid the "disjointed" project management pitfalls Etienne and Kristy discussed. FEEDBACK CALL-TO-ACTION What are your biggest hurdles in managing the full medical device life cycle? We want to hear from you. Whether it's a specific regulatory challenge or a topic suggestion for a future guest, send your thoughts to podcast@greenlight.guru [podcast@greenlight.guru]. We read every email and pride ourselves on giving personalized responses to our MedTech community.